Pasithea Therapeutics Publishes Study In Proceedings Of The National Academy Of Sciences That Shows An Increase In Α5 Integrin Expression In ALS Human And Mouse Brain Tissue, Targeting Α5 Integrin Results In Improved Survival And Motor Function
Portfolio Pulse from Happy Mohamed
Pasithea Therapeutics Corp. (NASDAQ:KTTA) has published a study in the Proceedings of the National Academy of Sciences that shows an increase in α5 integrin expression in ALS human and mouse brain tissue. The study also shows that targeting α5 integrin results in improved survival and motor function. The company's lead α5/β1 integrin drug candidate is expected to be selected in H2 2023.
August 01, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics' study showing increased α5 integrin expression in ALS brain tissue and improved survival and motor function when targeted could potentially boost the company's reputation and stock value. The selection of the lead drug candidate in H2 2023 could also have a positive impact.
The study's findings could potentially lead to a breakthrough in ALS treatment, which would significantly boost Pasithea Therapeutics' reputation in the biotech industry. This, in turn, could attract more investors, driving up the company's stock value. The selection of the lead drug candidate in H2 2023 could also generate positive anticipation among investors, further boosting the stock value.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100